دورية أكاديمية
Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome.
| العنوان: | Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. |
|---|---|
| المؤلفون: | Hitzler, Johann K, He, Wensheng, Doyle, John, Cairo, Mitchell, Camitta, Bruce M, Chan, Ka Wah, Diaz Perez, Miguel A, Fraser, Christopher, Gross, Thomas G, Horan, John T, Kennedy-Nasser, Alana A, Kitko, Carrie, Kurtzberg, Joanne, Lehmann, Leslie, O'Brien, Tracey, Pulsipher, Michael A, Smith, Franklin O, Zhang, Mei-Jie, Eapen, Mary, Carpenter, Paul A, CIBMTR Pediatric Cancer Working Committee |
| بيانات النشر: | Elsevier BV |
| سنة النشر: | 2022 |
| المجموعة: | Duke University Libraries: DukeSpace |
| مصطلحات موضوعية: | CIBMTR Pediatric Cancer Working Committee, Humans, Down Syndrome, Graft vs Host Disease, Recurrence, Antineoplastic Agents, Treatment Outcome, Remission Induction, Bone Marrow Transplantation, Hematopoietic Stem Cell Transplantation, Transplantation, Homologous, Risk Factors, Survival Analysis, Adolescent, Child, Preschool, Female, Male, Leukemia, Myeloid, Acute, Young Adult |
| الوصف: | Data on outcomes of allogeneic transplantation in children with Down syndrome and acute myelogenous leukemia (DS-AML) are scarce and conflicting. Early reports stress treatment-related mortality as the main barrier; a recent case series points to posttransplantation relapse. We reviewed outcome data for 28 patients with DS-AML reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2009 and performed a first matched-pair analysis of 21 patients with DS-AML and 80 non-DS AML controls. The median age at transplantation for DS-AML was 3 years, and almost half of the cohort was in second remission. The 3-year probability of overall survival was only 19%. In multivariate analysis, adjusting for interval from diagnosis to transplantation, risks of relapse (hazard ratio [HR], 2.84; P < .001; 62% versus 37%) and transplant-related mortality (HR, 2.52; P = .04; 24% versus 15%) were significantly higher for DS-AML compared to non-DS AML. Overall mortality risk (HR, 2.86; P < .001; 21% versus 52%) was significantly higher for DS-AML. Both transplant-related mortality and relapse contribute to higher mortality. Excess mortality in DS-AML patients can only effectively be addressed through an international multicenter effort to pilot strategies aimed at lowering both transplant-related mortality and relapse risks. |
| نوع الوثيقة: | article in journal/newspaper |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1083-8791 1523-6536 |
| العلاقة: | Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation; S1083-8791(13)00102-X; https://hdl.handle.net/10161/24688Test |
| الإتاحة: | https://hdl.handle.net/10161/24688Test |
| رقم الانضمام: | edsbas.BACB85B4 |
| قاعدة البيانات: | BASE |
Full Text Finder | تدمد: | 10838791 15236536 |
|---|